PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm

Phyu P. Aung, Narittee Sukswai, Reza Nejati, Sanam Loghavi, Weina Chen, Carlos A. Torres-Cabala, C. Cameron Yin, Marina Konopleva, Xiaofeng Zheng, Jing Wang, Zhenya Tang, L. Jeffrey Medeiros, Victor G. Prieto, Naveen Pemmaraju, Joseph D. Khoury

Research output: Contribution to journalArticle

Abstract

Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have poor outcomes despite intensive chemotherapy, underscoring the need for novel therapeutic approaches. The expression status of PD1/PD-L1 in BPDCN remains unknown. We evaluated PD1/PD-L1 by immunohistochemistry and RNAseq expression profiling in a cohort of BPDCN patients. The study group included 28 patients with a median age of 66.8 years (range, 22.8–86.7), 22 men and 6 women. PD-L1 expression was detected by immunohistochemistry in 10/21 (47.6%) cases. PD-L1 expression had a median H-score of 157. The H-score was ≥60 in 7 patients. PD-L1 protein levels (H-score) were proportional to normalized PD-L1 mRNA transcript levels (CD274 mRNA). In addition, high-level PD-L1 expression correlated with higher numbers of PD1-positive cells within BPDCN tumors. There was no correlation between clinicopathologic characteristics and PD-L1 expression status. Similarly, there was no significant difference in overall survival between patients with PD-L1-positive and PD-L1-negative BPDCN (median 12 vs. 23 month, respectively; p = 0.743). In conclusion, PD-L1 expression by tumor cells is detectable in a sizeable subset of patients with BPDCN, suggesting that exploration of the effectiveness of therapeutic inhibition of the PD1/PD-L1 axis in patients with refractory or progressive BPDCN is warranted.

Original languageEnglish (US)
Article number695
JournalCancers
Volume11
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Dendritic Cells
Neoplasms
Immunohistochemistry
Messenger RNA
Drug Therapy
Survival
Therapeutics

Keywords

  • Immune checkpoint regulation
  • Immunotherapy
  • PD-L1
  • RNA sequencing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aung, P. P., Sukswai, N., Nejati, R., Loghavi, S., Chen, W., Torres-Cabala, C. A., ... Khoury, J. D. (2019). PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm. Cancers, 11(5), [695]. https://doi.org/10.3390/cancers11050695

PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm. / Aung, Phyu P.; Sukswai, Narittee; Nejati, Reza; Loghavi, Sanam; Chen, Weina; Torres-Cabala, Carlos A.; Yin, C. Cameron; Konopleva, Marina; Zheng, Xiaofeng; Wang, Jing; Tang, Zhenya; Medeiros, L. Jeffrey; Prieto, Victor G.; Pemmaraju, Naveen; Khoury, Joseph D.

In: Cancers, Vol. 11, No. 5, 695, 01.05.2019.

Research output: Contribution to journalArticle

Aung, PP, Sukswai, N, Nejati, R, Loghavi, S, Chen, W, Torres-Cabala, CA, Yin, CC, Konopleva, M, Zheng, X, Wang, J, Tang, Z, Medeiros, LJ, Prieto, VG, Pemmaraju, N & Khoury, JD 2019, 'PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm', Cancers, vol. 11, no. 5, 695. https://doi.org/10.3390/cancers11050695
Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA et al. PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm. Cancers. 2019 May 1;11(5). 695. https://doi.org/10.3390/cancers11050695
Aung, Phyu P. ; Sukswai, Narittee ; Nejati, Reza ; Loghavi, Sanam ; Chen, Weina ; Torres-Cabala, Carlos A. ; Yin, C. Cameron ; Konopleva, Marina ; Zheng, Xiaofeng ; Wang, Jing ; Tang, Zhenya ; Medeiros, L. Jeffrey ; Prieto, Victor G. ; Pemmaraju, Naveen ; Khoury, Joseph D. / PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm. In: Cancers. 2019 ; Vol. 11, No. 5.
@article{839fda3a65d342a9934834cf9122195a,
title = "PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm",
abstract = "Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have poor outcomes despite intensive chemotherapy, underscoring the need for novel therapeutic approaches. The expression status of PD1/PD-L1 in BPDCN remains unknown. We evaluated PD1/PD-L1 by immunohistochemistry and RNAseq expression profiling in a cohort of BPDCN patients. The study group included 28 patients with a median age of 66.8 years (range, 22.8–86.7), 22 men and 6 women. PD-L1 expression was detected by immunohistochemistry in 10/21 (47.6{\%}) cases. PD-L1 expression had a median H-score of 157. The H-score was ≥60 in 7 patients. PD-L1 protein levels (H-score) were proportional to normalized PD-L1 mRNA transcript levels (CD274 mRNA). In addition, high-level PD-L1 expression correlated with higher numbers of PD1-positive cells within BPDCN tumors. There was no correlation between clinicopathologic characteristics and PD-L1 expression status. Similarly, there was no significant difference in overall survival between patients with PD-L1-positive and PD-L1-negative BPDCN (median 12 vs. 23 month, respectively; p = 0.743). In conclusion, PD-L1 expression by tumor cells is detectable in a sizeable subset of patients with BPDCN, suggesting that exploration of the effectiveness of therapeutic inhibition of the PD1/PD-L1 axis in patients with refractory or progressive BPDCN is warranted.",
keywords = "Immune checkpoint regulation, Immunotherapy, PD-L1, RNA sequencing",
author = "Aung, {Phyu P.} and Narittee Sukswai and Reza Nejati and Sanam Loghavi and Weina Chen and Torres-Cabala, {Carlos A.} and Yin, {C. Cameron} and Marina Konopleva and Xiaofeng Zheng and Jing Wang and Zhenya Tang and Medeiros, {L. Jeffrey} and Prieto, {Victor G.} and Naveen Pemmaraju and Khoury, {Joseph D.}",
year = "2019",
month = "5",
day = "1",
doi = "10.3390/cancers11050695",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm

AU - Aung, Phyu P.

AU - Sukswai, Narittee

AU - Nejati, Reza

AU - Loghavi, Sanam

AU - Chen, Weina

AU - Torres-Cabala, Carlos A.

AU - Yin, C. Cameron

AU - Konopleva, Marina

AU - Zheng, Xiaofeng

AU - Wang, Jing

AU - Tang, Zhenya

AU - Medeiros, L. Jeffrey

AU - Prieto, Victor G.

AU - Pemmaraju, Naveen

AU - Khoury, Joseph D.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have poor outcomes despite intensive chemotherapy, underscoring the need for novel therapeutic approaches. The expression status of PD1/PD-L1 in BPDCN remains unknown. We evaluated PD1/PD-L1 by immunohistochemistry and RNAseq expression profiling in a cohort of BPDCN patients. The study group included 28 patients with a median age of 66.8 years (range, 22.8–86.7), 22 men and 6 women. PD-L1 expression was detected by immunohistochemistry in 10/21 (47.6%) cases. PD-L1 expression had a median H-score of 157. The H-score was ≥60 in 7 patients. PD-L1 protein levels (H-score) were proportional to normalized PD-L1 mRNA transcript levels (CD274 mRNA). In addition, high-level PD-L1 expression correlated with higher numbers of PD1-positive cells within BPDCN tumors. There was no correlation between clinicopathologic characteristics and PD-L1 expression status. Similarly, there was no significant difference in overall survival between patients with PD-L1-positive and PD-L1-negative BPDCN (median 12 vs. 23 month, respectively; p = 0.743). In conclusion, PD-L1 expression by tumor cells is detectable in a sizeable subset of patients with BPDCN, suggesting that exploration of the effectiveness of therapeutic inhibition of the PD1/PD-L1 axis in patients with refractory or progressive BPDCN is warranted.

AB - Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have poor outcomes despite intensive chemotherapy, underscoring the need for novel therapeutic approaches. The expression status of PD1/PD-L1 in BPDCN remains unknown. We evaluated PD1/PD-L1 by immunohistochemistry and RNAseq expression profiling in a cohort of BPDCN patients. The study group included 28 patients with a median age of 66.8 years (range, 22.8–86.7), 22 men and 6 women. PD-L1 expression was detected by immunohistochemistry in 10/21 (47.6%) cases. PD-L1 expression had a median H-score of 157. The H-score was ≥60 in 7 patients. PD-L1 protein levels (H-score) were proportional to normalized PD-L1 mRNA transcript levels (CD274 mRNA). In addition, high-level PD-L1 expression correlated with higher numbers of PD1-positive cells within BPDCN tumors. There was no correlation between clinicopathologic characteristics and PD-L1 expression status. Similarly, there was no significant difference in overall survival between patients with PD-L1-positive and PD-L1-negative BPDCN (median 12 vs. 23 month, respectively; p = 0.743). In conclusion, PD-L1 expression by tumor cells is detectable in a sizeable subset of patients with BPDCN, suggesting that exploration of the effectiveness of therapeutic inhibition of the PD1/PD-L1 axis in patients with refractory or progressive BPDCN is warranted.

KW - Immune checkpoint regulation

KW - Immunotherapy

KW - PD-L1

KW - RNA sequencing

UR - http://www.scopus.com/inward/record.url?scp=85067038009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067038009&partnerID=8YFLogxK

U2 - 10.3390/cancers11050695

DO - 10.3390/cancers11050695

M3 - Article

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 5

M1 - 695

ER -